CA3140137A1 - Eltrombopag dosing regimen - Google Patents

Eltrombopag dosing regimen Download PDF

Info

Publication number
CA3140137A1
CA3140137A1 CA3140137A CA3140137A CA3140137A1 CA 3140137 A1 CA3140137 A1 CA 3140137A1 CA 3140137 A CA3140137 A CA 3140137A CA 3140137 A CA3140137 A CA 3140137A CA 3140137 A1 CA3140137 A1 CA 3140137A1
Authority
CA
Canada
Prior art keywords
eltrombopag
tapering
dose
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140137A
Other languages
English (en)
French (fr)
Inventor
Miona STANKOVIC
Nichola COOPER
Waleed GHANIMA
Francesco ZAJA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharmaceuticals Corp filed Critical Novartis Pharmaceuticals Corp
Publication of CA3140137A1 publication Critical patent/CA3140137A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3140137A 2019-05-14 2019-05-14 Eltrombopag dosing regimen Pending CA3140137A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/032171 WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Publications (1)

Publication Number Publication Date
CA3140137A1 true CA3140137A1 (en) 2020-11-19

Family

ID=67211802

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140137A Pending CA3140137A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Country Status (9)

Country Link
US (1) US20220313663A1 (cg-RX-API-DMAC7.html)
EP (1) EP3968984A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537883A (cg-RX-API-DMAC7.html)
KR (1) KR20220035036A (cg-RX-API-DMAC7.html)
AU (2) AU2019445762A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140137A1 (cg-RX-API-DMAC7.html)
IL (1) IL288078A (cg-RX-API-DMAC7.html)
MX (1) MX2021013971A (cg-RX-API-DMAC7.html)
WO (1) WO2020231407A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201406373A (zh) * 2012-06-29 2014-02-16 Shionogi & Co 含有具有血栓形成素受體促效作用之化合物之醫藥組合物

Also Published As

Publication number Publication date
JP2023182667A (ja) 2023-12-26
AU2019445762A1 (en) 2021-12-09
MX2021013971A (es) 2022-04-01
AU2023274065A1 (en) 2023-12-14
JP2022537883A (ja) 2022-08-31
US20220313663A1 (en) 2022-10-06
IL288078A (en) 2025-01-01
WO2020231407A1 (en) 2020-11-19
KR20220035036A (ko) 2022-03-21
EP3968984A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP7295305B2 (ja) ループス腎炎の治療のための改善されたプロトコル
TWI729022B (zh) 用於治療葡萄膜炎及黃斑水腫之包含il6r抗體的組合物與其使用方法
JP2024530954A5 (cg-RX-API-DMAC7.html)
Desideri et al. Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
JP2016516761A5 (cg-RX-API-DMAC7.html)
US9920131B2 (en) Dosage and administration of anti-EGFR therapeutics
JP2021152002A5 (cg-RX-API-DMAC7.html)
WO2020231408A1 (en) Eltrombopag dosing regimen
AU2023274065A1 (en) Eltrombopag dosing regimen
CN107249586A (zh) 用于治疗精神分裂症的伊潘立酮
US20230167189A1 (en) Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
JP2024516886A5 (cg-RX-API-DMAC7.html)
McNeil Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity
JP2020172471A (ja) ヒト化抗ヒトcd26抗体を含有する医薬組成物
Shah et al. Clinical Trials in Age-related Macular Degeneration-IV
Delaney et al. Emerging treatments for non-infectious uveitis
Dalton et al. Ranibizumab achieves higher BCVA gains for BRVO in COMRADE-B.
Narayanan et al. Corticosteroids: Triamcinolone, Dexamethasone
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf
Bilgec et al. Intravitreal Dexamethasone Implant (Ozurdex) for Macular Edema Secondary to Retinal Vein Occlusion
WO2019231800A1 (en) Anti-cgrp antibodies for treating menstrual-related migraines
Gillies CLINICAL EFFICACY SAFETY PHARMACOLOGY PHARMACOKINETICS ROUTE OF ADMINISTRATION
INGERMAN et al. Emerging Treatments

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240403

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241221

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241221

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250610

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708